SCHEMBL4470285

SCHEMBL4470285

CNC(=O)c1cc(Oc2cccc(-c3c[nH]c(C(=O)Nc4cc(C(F)(F)F)ccc4N(C)C)c3)c2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.50
RET P07949 3/20 0.50
PLK4 O00444 2/20 0.50
AURKA O14965 2/20 0.50
MAPK13 O15264 2/20 0.50
MAP4K4 O95819 2/20 0.50
ABL1 P00519 2/20 0.50
LCK P06239 2/20 0.50
FYN P06241 2/20 0.50
LYN P07948 2/20 0.50
SRC P12931 2/20 0.50
RPS6KB1 P23443 2/20 0.50
EPHA2 P29317 2/20 0.50
AXL P30530 2/20 0.50
FRK P42685 2/20 0.50
MAPK9 P45984 2/20 0.50
BLK P51451 2/20 0.50
CAMK2B Q13554 2/20 0.50
NTRK3 Q16288 2/20 0.50
MAPK14 Q16539 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9100015 0.89 KDR (0.38) KDRRETPLK4AURKAMAPK13
SCHEMBL4463483 0.88 RAF1 (0.64) KDRRETPLK4AURKAMAPK13
SCHEMBL9106204 0.86 KDR (0.65) KDRRETPLK4AURKAMAPK13
SCHEMBL4466760 0.83 KDR (0.70) KDRRETPLK4AURKAMAPK13
SCHEMBL4463609 0.82 RAF1 (0.51) KDRRETPLK4AURKAMAPK13
SCHEMBL4470287 0.81 KDR (0.50) KDRRETPLK4AURKAMAPK13
SCHEMBL4459588 0.81 KDR (0.44) KDRRETPLK4AURKAMAPK13
SCHEMBL4473424 0.80 KDR (0.54) KDRRETPLK4AURKAMAPK13
SCHEMBL4469831 0.80 RAF1 (0.71) KDRRETPLK4AURKAMAPK13
SCHEMBL4469341 0.80 BRAF (0.56) KDRRETPLK4AURKAMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685125-B1 Pyrrole derivatives useful for the treatment of proliferative diseases MERCK PATENT GMBH (DE) 2012-06-06 EP claimed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US claimed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US claimed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US disclosed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149594-A1 Pyrrole derivatives RAF1, BRAF, ARAF KDR 2076/4885RET 36/4885PLK4 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.